Sona Kamat, MD
Rheumatology · Saint Louis, MONPI 1407896129
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $172,550 of the $267,813 with a category attached, or 64.4%. 38 manufacturers reported payments, led by AbbVie at 30.2% of the total. Reporting peaked in 2019 at $85,790 and has fallen 61.0% since, to $33,421 in 2025. Among rheumatology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,348 payments — averaging $198.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$81K
- Lilly USA, LLC$67K
- Amgen$56K
- Novartis$29K
- UCB, Inc.$19K
- E.r. Squibb & Sons, L.L.C.$5K
- plus $12K from 32 others
Across 40 payments — averaging $16,579 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$333K
- Astrazeneca UK Limited$321K
- Eli Lilly$8K
- Pfizer$1K
What the payments were for
- Consulting fees$44,49917%
- Speaking & faculty fees$172,55064%
- Grants$2400%
- Travel & lodging$24,0579%
- Food & beverage$26,03210%
- Education$4360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 235 | $80,800 |
| Lilly USA, LLC | 164 | $67,372 |
| Amgen(2 entities) | 248 | $55,665 |
| Novartis | 83 | $28,639 |
| UCB, Inc. | 118 | $18,731 |
| E.r. Squibb & Sons, L.L.C. | 39 | $5,008 |
| Johnson & Johnson | 104 | $2,297 |
| Janssen Global Services, LLC | 1 | $1,400 |
| Pfizer | 120 | $1,190 |
| Merck | 8 | $1,010 |
| AstraZeneca(2 entities) | 38 | $970 |
| Novo Nordisk | 8 | $778 |
| GSK | 33 | $589 |
| Genentech USA, Inc. | 20 | $457 |
| Janssen Scientific Affairs, LLC | 5 | $395 |
| Sanofi | 12 | $300 |
| Bristol Myers Squibb | 24 | $292 |
| ANI Pharmaceuticals, Inc. | 8 | $247 |
| Mallinckrodt Hospital Products Inc. | 6 | $223 |
| Zyla Life Sciences, Inc. | 14 | $171 |
| Octapharma USA, Inc. | 5 | $165 |
| Organon | 9 | $153 |
| Mallinckrodt Enterprises LLC | 5 | $132 |
| Antares Pharma, Inc. | 12 | $131 |
| Sobi, Inc | 5 | $131 |
| Teva Pharmaceuticals USA, Inc. | 3 | $117 |
| Sanofi-aventis U.S. LLC | 2 | $110 |
| Fresenius Kabi USA, LLC | 5 | $88 |
| Medexus Pharma, Inc. | 4 | $47 |
| Aurinia Pharma U.S., Inc. | 2 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $26 |
| Boehringer Ingelheim | 1 | $26 |
| Biogen | 1 | $23 |
| Invivyd Inc | 1 | $22 |
| Assertio Therapeutics, Inc. | 1 | $19 |
| Iroko Pharmaceuticals, LLC | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$267,813 in reported general payments places this provider in the 95th percentile of 134 rheumatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 27 | $1,208 |
| Leflunomide | 11 | $333 |
| Tramadol Hcl | 14 | $120 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Saint Louis
- Adam KilianSaint Louis$565K
- Alfred KimSaint Louis$486K
- Richard BrasingtonSaint Louis$100K
- Akgun InceSaint Louis$45K
- Joseph StauberSaint Louis$37K
- Alissa ChandlerSaint Louis$37K
- Chad RonholmSaint Louis$27K
- Sandra HoffmannSaint Louis$23K
- John BuddSaint Louis$17K
- Michael PaleySaint Louis$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.